Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis

  Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of
  AN2728 in Mild-to-Moderate Atopic Dermatitis

Business Wire

PALO ALTO, Calif. -- March 31, 2014

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the first patient
has been enrolled in the Phase 3 trial of AN2728, a novel boron-based
phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of
mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash
characterized by inflammation and itch and affects approximately 10% - 20% of
infants and young children.

The Phase 3 trial consists of two multi-center, double-blind,
vehicle-controlled studies which will enroll approximately 750 subjects per
study who will be randomized 2:1 (active:vehicle). Both studies will be
conducted at multiple sites and enroll subjects ages two years and older with
mild-to-moderate atopic dermatitis, defined as an Investigator Static Global
Assessment (ISGA) score of 2 (“mild”) or 3 (“moderate”). The ISGA is a 5-point
scale from 0 (“clear”) to 4 (“severe”). AN2728 Ointment, 2% will be applied
twice daily for 28 days. The primary efficacy endpoint will be treatment
success at Day 29, defined as an ISGA of “Clear”or “Almost Clear”with at
least a 2-grade improvement from baseline. Secondary endpoints will include an
ISGA of “Clear”or “Almost Clear” at Day 29 as well as time to treatment
success. Safety evaluation will include reported adverse events, safety
laboratory tests, and vital signs.

Subjects who complete either Phase 3 study will have the option to enroll in a
long-term safety trial to evaluate the safety of intermittent use of AN2728
Ointment, 2% for up to 12 months. At least 100 subjects will be enrolled for
12 months and at least 300 subjects will be enrolled for 6 months, during
which time subjects will be treated as needed under the direction of the

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — Kerydin (tavaborole), an antifungal for the treatment
of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to Kerydin and
AN2728, respectively, and AN3365, an antibiotic for the treatment of
infections caused by Gram-negative bacteria. Anacor has also discovered three
other compounds that have been out-licensed for further development — one is
licensed to Eli Lilly and Company for the treatment of an animal health
indication, the second compound, AN5568, also referred to as SCYX-7158, is
licensed to Drugs for Neglected Diseases initiative, or DNDi, for human
African trypanosomiasis (HAT, or sleeping sickness) and the third compound is
licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also
has a pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding our Phase 3 clinical development of AN2728. These forward looking
statements involve known and unknown risks, uncertainties and other factors
that could cause actual levels of activity, performance or achievement to
differ materially from those expressed or implied by these forward-looking
statements, including risks related to enrollment and successful completion of
clinical trials, risks of unforeseen side effects and risks related to
regulatory approval of new drug candidates. Reference should be made to
Anacor's Annual Report on Form 10-K for the year endedDecember 31, 2013 filed
with theSecurities and Exchange Commissionunder the heading "Risk Factors".
These statements reflect the views of Anacor as of the date of this press
release with respect to future events and, except as required by law, it
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise
after the date of this press release.


Anacor Pharmaceuticals
DeDe Sheel
Senior Director, 650-543-7575
Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.